vers la météo de la validation par utilisateur
+-----------------------------------------------COMP:V-N(In)-----------------------------------------------+ | +----------------------------------------COMP:V-N(from)----------------------------------------+ | | +----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------------OBJ:V-N-------------------------------------+ | | | | +---------------------------------SUBJ:V-N--------------------------------+ | | | | +----------------------------OBJ:V-N---------------------------+ | +---------------------------OBJ:V-N--------------------------+ | | | | +-----------------------SUBJ:V-N-----------------------+ | +--------------COMP:V-N(by)-------------+ +--------------APPOS--------------+ | | | | +-------------OBJ:V-N------------+ | | | +MOD_ATT:N-AD+ +-MOD_ATT:N-ADJ-+ +--MOD_ATT:N-N--+ | +MOD_ATT:+ | | | | +-MOD_ATT:N-N-+--SUBJ:V-N-+-OBJ:V-N-+MOD_P+ | | | +MOD:ADJ-AD+ +MOD_A+ | +MOD_ATT:+ | +MOD_ATT:N+MOD_ATT:N-+ | | | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from __SP__ , 5 aminoimidazole 4 carboxamide ribonucleoside decreases quantity of __NODE__ that is increased by constitutively active mutant SREBP 1c [__NODE__] protein ( C terminal truncation 404 End ) . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (ribonucleoside,carboxamide) OBJ:V-N (decrease,4) SUBJ:V-N (decrease,ribonucleoside) OBJ:V-N (decrease,quantity) MOD_POST:N-ADJ (quantity,of) OBJ:V-N (__NODE__,aminoimidazole) SUBJ:V-N (__NODE__,4) OBJ:V-N (be,5) SUBJ:V-N (be,aminoimidazole) COMP:V-N(In) (increase,islet) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,5) COMP:V-N(by) (increase,SREBP) OBJ:V-N (increase,protein) MOD:ADJ-ADV (active,constitutively) MOD_ATT:N-ADJ (SREBP,active) MOD_ATT:N-ADJ (SREBP,mutant) MOD_ATT:N-ADJ (protein,1c) MOD_ATT:N-N (protein,[__NODE__]) APPOS (protein,end) MOD_ATT:N-N (truncation,C) MOD_ATT:N-N (truncation,terminal) MOD_ATT:N-N (end,truncation)
+-----------------------------------------------COMP:V-N(In)-----------------------------------------------+ | +----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------------OBJ:V-N-------------------------------------+ | | | +---------------------------------SUBJ:V-N--------------------------------+ | | | +----------------------------OBJ:V-N---------------------------+ | +---------------------------OBJ:V-N--------------------------+ | | | +-----------------------SUBJ:V-N-----------------------+ | +--------------COMP:V-N(by)-------------+ +--------------APPOS--------------+ | | | +-------------OBJ:V-N------------+ | | | +MOD_ATT:N-AD+ +-MOD_ATT:N-ADJ-+ +--MOD_ATT:N-N--+ | +MOD_ATT:+COMP:N-N(fr+ | | | +-MOD_ATT:N-N-+--SUBJ:V-N-+-OBJ:V-N-+MOD_P+ | | | +MOD:ADJ-AD+ +MOD_A+ | +MOD_ATT:+ | +MOD_ATT:N+MOD_ATT:N-+ | | | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from __SP__ , 5 aminoimidazole 4 carboxamide ribonucleoside decreases quantity of __NODE__ that is increased by constitutively active mutant SREBP 1c [__NODE__] protein ( C terminal truncation 404 End ) . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (ribonucleoside,carboxamide) OBJ:V-N (decrease,4) SUBJ:V-N (decrease,ribonucleoside) OBJ:V-N (decrease,quantity) MOD_POST:N-ADJ (quantity,of) OBJ:V-N (__NODE__,aminoimidazole) SUBJ:V-N (__NODE__,4) OBJ:V-N (be,5) SUBJ:V-N (be,aminoimidazole) COMP:V-N(In) (increase,islet) SUBJ:V-N (increase,5) COMP:V-N(by) (increase,SREBP) OBJ:V-N (increase,protein) MOD:ADJ-ADV (active,constitutively) MOD_ATT:N-ADJ (SREBP,active) MOD_ATT:N-ADJ (SREBP,mutant) MOD_ATT:N-ADJ (protein,1c) MOD_ATT:N-N (protein,[__NODE__]) APPOS (protein,end) MOD_ATT:N-N (truncation,C) MOD_ATT:N-N (truncation,terminal) MOD_ATT:N-N (end,truncation)
+-----------------------------------------------COMP:V-N(In)-----------------------------------------------+ | +----------------------------------------COMP:V-N(from)----------------------------------------+ | | +----------------------------------------SUBJ:V-N----------------------------------------+ | | +--------------------------------------OBJ:V-N-------------------------------------+ | | | | +---------------------------------SUBJ:V-N--------------------------------+ | | | | +----------------------------OBJ:V-N---------------------------+ | +---------------------------OBJ:V-N--------------------------+ | | | | +-----------------------SUBJ:V-N-----------------------+ | +--------------COMP:V-N(by)-------------+ +--------------APPOS--------------+ | | | | +-------------OBJ:V-N------------+ | | | +MOD_ATT:N-AD+ +-MOD_ATT:N-ADJ-+ +--MOD_ATT:N-N--+ | +MOD_ATT:+ | | | | +-MOD_ATT:N-N-+--SUBJ:V-N-+-OBJ:V-N-+MOD_P+ | | | +MOD:ADJ-AD+ +MOD_A+ | +MOD_ATT:+ | +MOD_ATT:N+MOD_ATT:N-+ | | | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from __SP__ , 5 aminoimidazole 4 carboxamide ribonucleoside decreases quantity of __NODE__ that is increased by constitutively active mutant SREBP 1c [__NODE__] protein ( C terminal truncation 404 End ) . MOD_ATT:N-ADJ (islet,pancreatic) MOD_ATT:N-N (ribonucleoside,carboxamide) OBJ:V-N (decrease,4) SUBJ:V-N (decrease,ribonucleoside) OBJ:V-N (decrease,quantity) MOD_POST:N-ADJ (quantity,of) OBJ:V-N (__NODE__,aminoimidazole) SUBJ:V-N (__NODE__,4) OBJ:V-N (be,5) SUBJ:V-N (be,aminoimidazole) COMP:V-N(In) (increase,islet) COMP:V-N(from) (increase,__SP__) SUBJ:V-N (increase,5) COMP:V-N(by) (increase,SREBP) OBJ:V-N (increase,protein) MOD:ADJ-ADV (active,constitutively) MOD_ATT:N-ADJ (SREBP,active) MOD_ATT:N-ADJ (SREBP,mutant) MOD_ATT:N-ADJ (protein,1c) MOD_ATT:N-N (protein,[__NODE__]) APPOS (protein,end) MOD_ATT:N-N (truncation,C) MOD_ATT:N-ADJ (truncation,terminal) MOD_ATT:N-N (end,truncation)
+-----------------------------------------------COMP:V-N(In)-----------------------------------------------+ | +----------------------------------------SUBJ:V-N----------------------------------------+ | +--------------------------------------OBJ:V-N-------------------------------------+ | | | +---------------------------------SUBJ:V-N--------------------------------+ | | | +----------------------------OBJ:V-N---------------------------+ | +---------------------------OBJ:V-N--------------------------+ | | | +-----------------------SUBJ:V-N-----------------------+ | +--------------COMP:V-N(by)-------------+ +--------------APPOS--------------+ | | | +-------------OBJ:V-N------------+ | | | +MOD_ATT:N-AD+ +-MOD_ATT:N-ADJ-+ +--MOD_ATT:N-N--+ | +MOD_ATT:+COMP:N-N(fr+ | | | +-MOD_ATT:N-N-+--SUBJ:V-N-+-OBJ:V-N-+MOD_P+ | | | +MOD:ADJ-AD+ +MOD_A+ | +MOD_ATT:+ | +MOD_ATT:N+MOD_ATT:N-+ | | | | | | | | | | | | | | | | | | | | | | | | | In pancreatic islets from __SP__ , 5 aminoimidazole 4 carboxamide ribonucleoside decreases quantity of __NODE__ that is increased by constitutively active mutant SREBP 1c [__NODE__] protein ( C terminal truncation 404 End ) . MOD_ATT:N-ADJ (islet,pancreatic) COMP:N-N(from) (islet,__SP__) MOD_ATT:N-N (ribonucleoside,carboxamide) OBJ:V-N (decrease,4) SUBJ:V-N (decrease,ribonucleoside) OBJ:V-N (decrease,quantity) MOD_POST:N-ADJ (quantity,of) OBJ:V-N (__NODE__,aminoimidazole) SUBJ:V-N (__NODE__,4) OBJ:V-N (be,5) SUBJ:V-N (be,aminoimidazole) COMP:V-N(In) (increase,islet) SUBJ:V-N (increase,5) COMP:V-N(by) (increase,SREBP) OBJ:V-N (increase,protein) MOD:ADJ-ADV (active,constitutively) MOD_ATT:N-ADJ (SREBP,active) MOD_ATT:N-ADJ (SREBP,mutant) MOD_ATT:N-ADJ (protein,1c) MOD_ATT:N-N (protein,[__NODE__]) APPOS (protein,end) MOD_ATT:N-N (truncation,C) MOD_ATT:N-ADJ (truncation,terminal) MOD_ATT:N-N (end,truncation)